Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Eventide Asset Management LLC reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 125,902 shares of the biopharmaceutical company’s stock after selling 40,548 shares during the period. Eventide Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $41,053,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock worth $4,336,064,000 after purchasing an additional 240,534 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after buying an additional 185,783 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after buying an additional 75,936 shares during the last quarter. Finally, Norges Bank bought a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth about $662,837,000. 92.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ALNY has been the topic of several research analyst reports. Royal Bank Of Canada upped their target price on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research note on Friday, September 19th. Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Piper Sandler restated an “overweight” rating and issued a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $482.71.

Alnylam Pharmaceuticals Stock Down 3.7%

Shares of ALNY stock opened at $397.55 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The stock has a market cap of $52.52 billion, a P/E ratio of 1,656.46 and a beta of 0.30. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The company has a 50 day simple moving average of $452.35 and a two-hundred day simple moving average of $406.45.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $451.27, for a total value of $4,512,700.00. Following the transaction, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at approximately $29,517,119.43. This trade represents a 13.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 60,328 shares of company stock worth $27,288,993 over the last three months. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.